R 568 hydrochloridePositive allosteric modulator of the human calcium-sensing receptor CAS# 177172-49-5 |
- Anguizole
Catalog No.:BCC1365
CAS No.:442666-98-0
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 177172-49-5 | SDF | Download SDF |
PubChem ID | 158796 | Appearance | Powder |
Formula | C18H23Cl2NO | M.Wt | 340.29 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (146.93 mM; Need ultrasonic) | ||
Chemical Name | 3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine;hydrochloride | ||
SMILES | CC(C1=CC(=CC=C1)OC)NCCCC2=CC=CC=C2Cl.Cl | ||
Standard InChIKey | YJXUXANREVNZLH-PFEQFJNWSA-N | ||
Standard InChI | InChI=1S/C18H22ClNO.ClH/c1-14(16-8-5-10-17(13-16)21-2)20-12-6-9-15-7-3-4-11-18(15)19;/h3-5,7-8,10-11,13-14,20H,6,9,12H2,1-2H3;1H/t14-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Positive allosteric modulator and allosteric agonist of the human calcium-sensing receptor (hCaSR). Exhibits calcimimetic activity. Has the ability to restore function to hCaSR mutants that cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). Exerts a suppressive effect on parathyroid (PT) hormone secretion; inhibits PT cell proliferation in rats with renal insufficiency. |
R 568 hydrochloride Dilution Calculator
R 568 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9387 mL | 14.6933 mL | 29.3867 mL | 58.7734 mL | 73.4667 mL |
5 mM | 0.5877 mL | 2.9387 mL | 5.8773 mL | 11.7547 mL | 14.6933 mL |
10 mM | 0.2939 mL | 1.4693 mL | 2.9387 mL | 5.8773 mL | 7.3467 mL |
50 mM | 0.0588 mL | 0.2939 mL | 0.5877 mL | 1.1755 mL | 1.4693 mL |
100 mM | 0.0294 mL | 0.1469 mL | 0.2939 mL | 0.5877 mL | 0.7347 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ambrisentan
Catalog No.:BCC4887
CAS No.:177036-94-1
- 2alpha,19alpha-Dihydroxy-3-oxo-urs-12-en-28-oic acid
Catalog No.:BCN7406
CAS No.:176983-21-4
- LY 320135
Catalog No.:BCC7346
CAS No.:176977-56-3
- CCT007093
Catalog No.:BCC5147
CAS No.:176957-55-4
- Metergoline
Catalog No.:BCC6709
CAS No.:17692-51-2
- Homoplantaginin
Catalog No.:BCN2488
CAS No.:17680-84-1
- (RS)-3,4-DCPG
Catalog No.:BCC7045
CAS No.:176796-64-8
- Ageratochromene dimer
Catalog No.:BCN8110
CAS No.:17678-76-1
- Neoruscogenin
Catalog No.:BCN8168
CAS No.:17676-33-4
- trans-Hinokiresinol
Catalog No.:BCN1130
CAS No.:17676-24-3
- Phorbol
Catalog No.:BCN3726
CAS No.:17673-25-5
- KN-92
Catalog No.:BCC1680
CAS No.:176708-42-2
- 26-O-Acetylsootepin A
Catalog No.:BCN7699
CAS No.:1772588-99-4
- Aglain B
Catalog No.:BCN6636
CAS No.:177262-32-7
- DBeQ
Catalog No.:BCC3916
CAS No.:177355-84-9
- Aglain C
Catalog No.:BCN6604
CAS No.:177468-85-8
- 2-Amino-5-nitrobenzophenone
Catalog No.:BCC8537
CAS No.:1775-95-7
- Flavokawain B
Catalog No.:BCN3568
CAS No.:1775-97-9
- ZK 164015
Catalog No.:BCC7272
CAS No.:177583-70-9
- Glycerol 1-(26-hydroxyhexacosanoate)
Catalog No.:BCN1131
CAS No.:177602-14-1
- MNITMT
Catalog No.:BCC7382
CAS No.:177653-76-8
- NKP608
Catalog No.:BCC1802
CAS No.:177707-12-9
- Proxyfan oxalate
Catalog No.:BCC7378
CAS No.:177708-09-7
- Calystegine N1
Catalog No.:BCN1866
CAS No.:177794-03-5
Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor.[Pubmed:19759318]
J Pharmacol Exp Ther. 2009 Dec;331(3):775-86.
Over 257 mutations in the human calcium-sensing receptor (hCaSR) gene have been reported. Heterozygous inactivating mutations can result in familial hypocalciuric hypercalcemia (FHH), whereas homozygous inactivating mutations can cause life-threatening neonatal severe hyperparathyroidism (NSHPT). Activating mutations in the hCaSR can result in hypercalciuria and hypocalcemia. A recent publication on the successful treatment of a patient suffering from FHH with the hCaSR positive allosteric modulator cinacalcet prompted our interest in exploring the molecular pharmacology of calcimimetics to correct signaling defects associated with inactivating hCaSR mutations. We prepared 11 mutant hCaSRs, previously identified in patients suffering from NSHPT or FHH, and tested their ability to couple to inositol phosphate accumulation and intracellular calcium mobilization in transiently transfected human embryonic kidney 293 and Chines hamster ovary cells using the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine]. We found that extracellular Ca(2+) was significantly less potent on the mutated receptors compared with wild-type hCaSR. However, R-568 was able to enhance the potency of extracellular Ca(2+) toward the mutant hCaSRs. Furthermore, R-568 increased the maximal agonist response on several of the mutant CaSRs. We applied a novel operational model of allosteric modulation/agonism that provided a common mechanism to account for the behavior of the wild-type and mutant hCaSRs. The data provide evidence for the potential use of calcimimetics to treat diseases such as FHH and NSHPT where severe hypercalcemia can be life-threatening.
NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.[Pubmed:10411552]
J Pharmacol Exp Ther. 1999 Aug;290(2):473-9.
Calcimimetics like N-(3-[2-chlorophenyl]propyl)-(R)-alpha-methyl-3-methoxybenzylamine (NPS R-568) potentiate the effects of extracellular Ca(2+) on parathyroid Ca(2+) receptors and inhibit parathyroid hormone (PTH) secretion in vitro. When administered by gavage to normal rats in this study, NPS R-568 caused a rapid, dose-dependent (ED(50), 1.1 +/- 0.7 mg/kg) decrease in PTH levels that was paralleled by a subsequent decrease in plasma Ca(2+) (ED(50), 10.4 +/- 3.7 mg/kg). At higher doses (>/=3.3 mg/kg), PTH was reduced to a minimum level within 15 min, the duration of which was dose dependent. With doses of 10 to 100 mg/kg, the hypocalcemia was rapid in onset (<30 min) and, at 33 to 100 mg/kg, persisted for >24 h. Neither the magnitude nor the kinetics of the hypocalcemic response was affected by total nephrectomy, demonstrating that NPS R-568 does not induce hypocalcemia by acting on renal Ca(2+) receptors to increase Ca(2+) excretion. In contrast, parathyroidectomy (intact thyroid) abolished the hypocalcemic response to NPS R-568, regardless of whether the rats were hypocalcemic or rendered acutely normo- or hypercalcemic by calcium infusion before dosing. These data show that the parathyroid Ca(2+) receptor can be selectively activated in vivo with a small organic compound to decrease plasma levels of PTH and Ca(2+) and thus define the mechanism of action of this compound in vivo. Moreover, the data add pharmacological support to the view that the Ca(2+) receptor is the primary molecular entity regulating systemic Ca(2+) homeostasis.
The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.[Pubmed:9399943]
J Clin Invest. 1997 Dec 15;100(12):2977-83.
Parathyroid (PT) cell hyperplasia is a common consequence of chronic renal insufficiency (CRI). NPS R-568 is a phenylalkylamine compound that acts as an agonist (calcimimetic) at the cell surface calcium receptor (CaR). To test the hypothesis that the CaR plays a role in PT hyperplasia in CRI, we tested the effect of NPS R-568 on PT cell proliferation in rats with renal insufficiency. Rats were subjected to 5/6 nephrectomy and then infused intraperitoneally with 5-bromodeoxyuridine (BrdU) to label S-phase cells. Two groups of nephrectomized rats received NPS R-568 by gavage twice daily for 4 d (1.5 and 15 mg/kg body wt). On day 5, the number of BrdU-positive PT cells of vehicle-treated nephrectomized rats was 2.6-fold greater than that of the sham-operated control. Low and high doses of NPS R-568 reduced the number of BrdU-positive PT cells by 20 and 50%, respectively. No changes in staining, however, were observed in ileal epithelial cells (CaR-negative) or in thyroidal C-cells (CaR-positive). Furthermore, the effect of NPS R-568 could not be explained by changes in serum 1,25(OH)2D3 or phosphorus. These results indicate that NPS R-568 suppresses PT cell proliferation in rats with renal insufficiency, and lend support to the linkage between the CaR and PT hyperplasia in CRI.